5 Things You Need to Know in Cervical Cancer: New and Emerging Agents

5 Things You Need to Know in Cervical Cancer: New and Emerging Agents

5 Things You Need to Know in Cervical Cancer: New and Emerging Agents

Critical unmet treatment needs remain for patients with second-line and later metastatic cervical cancer, but change is happening. Tune in now!

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials,including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Robert L. Coleman, MD, FACOG, FACS
    Chief Scientific Officer
    US Oncology Research
    Houston, TX

    Consulting Fees: AbbVie, Agenus, Alkermes, AstraZeneca, Clovis, Deciphera, Genelux, Genmab, GSK, Immunogen, Janssen, Merck, Novocure, OncoQuest, Onxeo, OncXerna, Regeneron, Roche/Genentech, VBL Therapeutics

    Research: AstraZeneca, Clovis, Genelux, Genmab, Merck, Immunogen, Janssen, Roche/Genentech

    Kathleen Moore, MD, MS
    Virginia Kerley Cade Endowed Chair, Cancer Development
    Professor of Gynecologic Oncology
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, OK

    Consulting Fees: AstraZeneca, Aravive, Alkermes, Blueprint, Corcept, Eisai, Elevar Therapeutics, ImmunoGen, I-Mab Biopharma, InxMed, Merck, Myriad Genetics, Mereo BioPharma, Mersana Therapeutics, VBL Therapeutics

    Research: PTC Therapeutics, Lilly, Merck, GlaxoSmithKline/Tesaro

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the mechanism of action, efficacy, and safety data for new and/or emerging treatments for cervical cancer.
    • Describe the benefits offered by participation in clinical trials for appropriate patients with cervical cancer.
  • Target Audience

    This activity is designed to meet the educational needs of community and academic gynecologic oncologists, as well as medical oncologists, ob-gyns, pathologists, and any other healthcare professionals involved in the management of gynecological cancers. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an educational grant from Genmab and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free